Clinical Trial Update: Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial update evaluating whether adding Triapine to Lutetium-177 dotatate improves outcomes for metastatic neuroendocrine tumors compa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor

Drugs mentioned

• Lutetium-177 dotatate (Lutetium-177 dotatate)
• Triapine (Triapine)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Neuroendocrine Tumor | Phase 2 | Status: ACTIVE_NOT_RECRUITING